PASLE: Premature Atherosclerosis in Systemic Lupus Erythematosus

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04037293
Collaborator
Beijing Municipal Science & Technology Commission (Other), National Natural Science Foundation of China (Other)
500
1
103
4.9

Study Details

Study Description

Brief Summary

Patients with SLE have increased rates of atherosclerosis, while the risk factors for atherosclerosis in those patients were not fully revealed. This study is an observational study to investigate the natural process and risk factors for atherosclerosis based on a Chinese SLE cohort. Carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) will be measured for each patient at baseline and 5-year follow-up. Blood tests including cholesterol levels, fasting plasma glucose levels and etc. will also be performed.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: CIMT and baPWV measurement

Detailed Description

Accelerated atherosclerosis is a major complication of systemic lupus erythematosus (SLE), and it leads to increased cardiovascular morbidity and mortality in patients with SLE. Prevention and intervention of premature atherosclerosis is beneficial for prognosis and survival of patients with SLE.

The primary aim of this study was to investigate the natural progress of carotid intima media thickness (CIMT) in 5 years, and examine the risk factors for progression of CIMT and atherosclerotic plaques based on a Chinese SLE cohort. The secondary aims of the study were to investigate progression of brachial-ankle pulse wave velocity (baPWV), and to examine the risk factors for increasing baPWV in patients with SLE.

Based on sample size calculation, 440 patients who meet the eligibility criteria will be enrolled in this study. All patients will be enrolled from Peking Union Medical College Hospital. After informed consent is obtained, the patients will be comprehensively evaluated from demographic characteristics, medical history, clinical assessments, laboratory tests results, CIMT and baPWV at baseline and 5-year follow-up. Descriptive analysis, univariate analysis, and multivariate analysis will be used to analyze the correlation between potential risk factors and CIMT/baPWV.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Premature Atherosclerosis in Systemic Lupus Erythematosus: a Prospective Cohort Study
Actual Study Start Date :
May 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Outcome Measures

Primary Outcome Measures

  1. quantitative change in CIMT from baseline [Year 5]

    quantitative changes in CIMT at 5-year follow-up from baseline will be documented

Secondary Outcome Measures

  1. quantitative change in baPWV from baseline [Year 5]

    quantitative changes in baPWV at 5-year follow-up from baseline will be documented

  2. Major cardiovascular events [5 years]

    the prevalence rate of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age≥18 years

  • Fulfillment of clinical classification criteria of SLE (four or more 1997 American College of Rheumatology classification criteria)

  • Provision of signed written informed consent

Exclusion Criteria:
  • Clinically overt coronary artery disease

  • A history of cardiovascular disease (previous stroke, heart failure, myocardial infarction, angina, or symptomatic PAD)

  • Malignancy

  • Pregnant/lactating women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking Union Medical College Hostipal Beijing Beijing China 100010

Sponsors and Collaborators

  • Peking Union Medical College Hospital
  • Beijing Municipal Science & Technology Commission
  • National Natural Science Foundation of China

Investigators

  • Study Chair: Shuyang Zhang, MD, Peking Union Medical College Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT04037293
Other Study ID Numbers:
  • JS-2057
First Posted:
Jul 30, 2019
Last Update Posted:
Jul 31, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peking Union Medical College Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 31, 2019